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IMMUNOCONTRACEPTION AS A TOOL FOR CONTROLLING
REPRODUCTION IN COYOTES
LOWELL A MILLER, U. S. Dcpatment of Agriculture, National Wildlife Research Center, 17 16 Heath Parkway,
Fott Collins. CO 80524

Abstract: The development of imrnunocontraception as a tool for population management of coyotes (Canis
la~.ans)and reduction of coyote predation may provide an environmentally safer alternative to pesticides. Because
they are proteins, ~mmunocontraceptivevaccines do not persist in the environment or bioaccumulate in the food
chain. The National Wildlife Research Center (NWRC) will examine the effects (immunological, holmonal and
behavioral) of treating penned coyotes with 2 imrnunocontraceptive vaccines: porcine zona pellucida (PZP) and
gonadotropin releas~nghoimone (GnRH). Initial studies will be conducted using traditional subcutaneous
injections; howeva-, the goal IS to develop an orally-deliverable immunocontraceptive vaccine as an alternative
tool for coyote populat~onmanagement

Livestock predation by coyotes is a chronic
conern of many sheep and goat ranchers. A 1990
survey estimated that, of the nearly 6 million lambs
born in the 16 westeln states, 549,000 lambs died
from all causes (Connolly 1992). Nearly 60% of
the losses were a I-esultof predators. Coyotes were
the main culprit, accounting for 70% of the
predator-caused mot-talltles The econonlic impact
on producers and consumers 11.1 1990 was approximately $1 1 4 million Desp~teintensive historical
control effol-1s in livestock production areas, and
despite spoil hunting and trapping for fur, coyotes
cont~nueto thrivc and expand their range, occu11-ing
w~delyacross North and Central America
Scientists at the Nat~onal Wildlife Research
Center and its prcdeccssor laboratories have conducted research for over 50 years on the problem of
livestock pl-edation by coyotes, and on developing
methods to min~mizepredation losses Available
techniques include husband~ypractices, shooting,
trapping, frightening devices, livestock guarding
dogs and tos~cants(Fall 1990). None of these
control methods is completely practical or effective
in all of the diverse situat~onsin which coyote
predation on l~vestockoccurs. Also, as the costs of
labor-intens~veskills and appl-oaches continue to
increase, new techn~quesare needed. Further,
coyotes are viewed increasingly by the public as a
desirable w~ldl~fe
speclcs Accordingly, efl'ective
nonlethal methods are being sought for resolution of

predation problems
Immunocontraception has been suggested as 1
nonlethal technique with application for reducing
coyote numbers In areas where they are causing
depredat~onlosses, or for managing the predatory
behavior of tell-~tol-ialpairs (Knowlton 1989).
However, private industry has had little economic
incentive to develop new materials for this use
because of the small quant~t~es
of materials that
would be used in predation control This situation
with mlmunoconkaceptionvaccines parallels that for
toxicants and other coyote predation control products (Linhai-t et al 1992).

Basics of immunocontraception

The neonatal veltebl-ate immune system develops a recogn~tionof "self' proteins, carbohydrates,
and holmones. This self recognition is essential,
since the production of antibodies against pathogenic
bacteria and viluses is necessary for survival.
However, the foimation of antibodies against "self'
can be an abnolmal destructive process, e.g., diseases like multiple sclerosis and arthritis.
The entire immune system is in constant surveillance to detelmine "self' vs "foreign" proteins. For
example, in the digestive ti-act, particles and organisms are examined and either tolerated or attacked
by antibodies The respiratory and intestinal muco-

sal surfaces contain various white blood cells (lymphocytes and macrophages) that are responsible for
generating specific immune responses. In the small
intestine, groups of lymphoid cells known as Peyer's
patches (PP) sample bits of food proteins and microorganisms as they pass through to determine if an
immune response will be directed against the incoming organism or food particle.
Anti-fertility vaccines are directed against "self'
reproductive antigens (holmones or proteins) to
which the recipient normally is immunologically
tolerant. These antigens are made "non-self' or
"foreign" by coupling them to a protein that is
recognized as fore~gnto the animal. As the animal'
immune system exanlines the conjugated self-fore~gn
protein, antibodies are produced to its own reproductive proterns and holmones This Induced
immune response agalnst "self' is the key to
immunocontracept~on The mfer-tility lasts as long as
there are suflic~entantrbod~esto intelfere wrth the
biological activ~tyof the targeted hormone or reproductive protein, usually 1-2 years.

Reproductive hormones and proteins involved in
immunocontraception

Immunocontraceptive vaccines can control
reproduction at various stages They can interrupt
the reproductrve activrty of both sexes by (a) interferrng with the biological act~vrtyof hornlones, (b)
block~ngspelni penetration of an ovulated egg, or
(c) preventing implantat~onand development of a
fertilized egg
Gonadotropin releasing holmone (GnRH) 1s
produced in the bra~nby the hypothalamus and
controls release of the pituitaly reproductive hormones follrcle stimulating holmone (FSH) and
luteinizing hormone (LH). These ho~monesin turn
control the hormonal hncrions of the gonads (ovaries and testes) Antibodies to the hypothalamic
hormone will reduce the crrculating level of
biologically-active GnIUI, thereby reducing the
release of subsequent reproductive hormones. The
reduction or absence of these hormones leads to
atrophy of the gonads, resulting in infertil~tyin both
sexes. Both avran and mammalian f o ~ m of
s GnRH
have been Identified.
The zona pellucida (ZP) is an acellular glyco-

protein surrounding the egg or oocyte. It is located
on the outer surface of the egg between the oocyte
and the granulosa cells. Antibodies to this glycoprotein layer result in infertility by 1 or both of these
actions: (a) blocking sperm from binding to the ZP
layer, and (b) interfering with oocyte maturat~on.
For a sperm to fertilize the egg, it must first bind to
a receptor on the ZP. An enzyme in the sperm
breaks down the ZP and allows the sperm passage
Into the ovum. Ant~bodiesto the ZP also prevent
fertilization by interfering with oocyte-granulosa cell
communication, resulting in the death of the developing oocyte (Dunbar and Schwoebel 1988).
Smce protein in the sperms' head normally bind
to the ZP receptor on the oocyte, antibodies to these
sperm prote~nscan be produced, by vaccination in
the female that are available to bind to sperm In the
oviduct. This prevents sperm fiom binding to the ZP
receptor Sperm protein immunocontraception IS
belng investrgated for contraception of the red fox
and the rabbit In Australia (Morel1 1993, TyndaleB~scoe199 1) A ZP protein has not been identified
in avian species, nor has the cross-reactivity of PZP
been tested in avian species.
Chorionic gonadotropin (CG) holmone, which
is produced by the Implanting embryo in some
species, induces the corpus luteum to continue
production of progesterone which is required for the
maintenance of pregnancy. Ant~bodiesto CG reduce
blood levels of this holmone and thereby prevent
~mplantationof the fertilized egg.
The riboflav~nrequirement of the developing
emblyo is sat~sfiedby active transport of this watersoluble v~taminacross the placenta. This transport
is provided by a gestatronal-specific carrier protern
called riboflavin carrier protein (RCP). RCP plays
a pivotal role in emb~yodevelopment in avian and
mammalian specles. Antibodies formed agalnst
RCP interfere w ~ t hplacental transfer of riboflavin,
thereby preventing development of the early embryo.
This technology probably would result in the least
change in social behav~orof the target species of any
of the proposed vaccines (Natraj et al. 1987, 1988).
Reproduction can be blocked at many sites in
the reproductive process; the above examples are the
sites where most investigative work has been done.
Behavioral and social changes in target animals
result~ngfrom specific vaccines may dictate the

vaccine of choice in each s~tuation(Jones 1982,
Griffin 1992).

Methods o f adrr~inisteringvaccincs

Subcutaneous or intramuscular (I M.) injection
are the traditional f o ~ m sof vaccine delivery. In
order to accomplish I M injections in free-roaming
an~mals,the vaccine must be del~veredby a dart or
a "bio-bullet" (Kirkpatrick et al. 1990, Tu~nerand
Kirkpatrick 199 1, Gall-ot et al. 1992, Tu~neret al.
1991, .I 992). Whlle these methods may be effective
in certain confined locations, they are impractical
when dealing with mobile wildl~fepopulations in
large open areas
.
Except for the oral polio vacclne introduced by
Dr. Sabul in the 1950s, oral vaccinat~onhas received
little attention fbr humans bccause it requires larger
quantities of vacclne and 1s less predictable than
subcutaneous or I M. routes In marnnials, oral
immunization takes place in the pha~yngealinlmune
follicles (e.g., the tonsils) and in the small intestine.
Thcre are thousands of immune foll~clesthroughout
tlie small intest~nc,wlth a h~gherconcentration in the
distal portion in most specles Vaccines, being
protern m nature, arc digested rap~dlyIn the stomach
when given orally, hence, ~mniunizationmust occur
e~therin thc pharyngeal arca 01-the vaccine needs a
protective capsule to sur\ll\re passage through the
stomach then be released In the small intestine
(McGhee et al. 1992)
The safest way to deliver the antlgen orally is to
protect it until it is taken up by the PP and del~vered
to macrophages A combination of 2 approaches
could lead to effective antlgen uptake and potentlation of mucosal immune response. (a) entel-ic
coat~ngof the ant~genresult~ngIn delive~yvehicles
that prevent degradation in the stomach but allow
absorption in the intestlnc, and (b) des~gningthe
vaccine to have enhanced attraction to the immune
follicles In the small ~ntestine
Recent underst:~ndingof the n~echanisn~s
by
wh~chpathogenic \Illuses and bacteria colonize and
Infect the intestinal tract has provided new insights
for developing successful and safe attenuated l ~ v eor
killed, oral vaccines. For example, a bacteria must
sul-vlve the stomach's acid and proteolytic enzymes
to successh~llyinfect the small intestine. After

surviving intact through the stomach, it must have
adhesive properties which allow it to adhere to and
colonize the intestinal wall, resulting in an infection.
Bacteria without adhesive properties will be carried
out of the gut w ~ t hthe waste material.
Liposomes are spherical, artificial biological
membranes made up of phospholipids and cholesterol that can be used to protect oral vaccines from
digestive tract degradation. Since the liposome
membrane contains lipids, which are stable in the
gastrointestinal tract, an antigen placed inside during
liposome synthesis is protected from gastrointestinal
degradation. Cholesterol in the membrane adds
stability and makes it attractive to macrophages in
the PP where the liposome is taken up rap~dly
because of the membrane's lipophilic nature. This
character~sticof the membrane causes the liposome
to simulate a microb~alcell when presented to the
immune system The liposome acts as an antigen
micl-ocanicrcapable of targeting the antigen directly
to the PP.
I-Iowever, before a hposome can be taken up by
the mas-ophages, it must bind to the mucosal sutface
of the ~ntestine;othe~wiseit will be swept out with
the waste material. This mucosal adhesive property
increases the mucosal uptake efficiency, thus requiring a smaller oral vacclne dose The most commonly used liposome adhesive is a nontoxlc form of
the bacterial lectin, cholera toxln (CT), a member of
a family of enterotoxlns produced by several strains
of enteropathogen~c bacteria (Holmgren et al.
1992). Lectins have multiple binding sites and can
bind to receptors on the liposome as well as to
intestinal receptors.
Recent advancements in molecular b~ologyand
immunology have provided us with new tools such
as "live vectors" as delive~yvehicles. The most
pmminent use ofthls technology In w~ldlifemanages deliver
ment is the use of the live vacclnla v i ~ u to
rabies vaccine orally to raccoons (Procyon lotor-)
and foxes ( V u l l ~ e svulpes). The attenuated vaccinia
virus, a member of the pox vlruses, was used as a
vaccine agalnst smallpox m humans for over 20
years. Using recombinant genetic engineer~ng,the
gene responsible for encoding of the rabies vlrus
glycoprotein was insetted into the vaccinia virus by
sclent~stsat the Wistar Institute This recombinant
pox vi~us,when given orally, was able to vaccinate
the target animal against rabies. The tonsil lymphoid

tissue is thought to initiate the immune response in
these target animals (USDA-APHIS 1991).

testinal environment and can induce a 500-fold
greater oral immune response as compared to free
antigens We plan to develop liposomes with a
cholera-toxin-B subunit on their surface to mimic the
adhesive properties of intestinal pathogens and
ensure optimal host immune response.

Live viral vectors potentially can be used to
deliver a contraceptive vaccine. This delivery
system is currently being tested in Australia
(Tyndale-Biscoe 1991).

Finally, prior to field use, U. S Food and Drug
Adrrunistiation approval of the safety and efficacy of
this new vaccine will be needed Extensive laboratory,fieldand product testing will be required before
this or other materials are available for use in management programs.

Potential of immunocontraccption in coyote
management
Immunocontraception as a technology is available today, but only for use in a laboratory setting
and pen studies. Immunocontraceptive vaccines are
being produced in limited quantities and animals
injected with these vaccines become infertile for 1 -3
years.
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